TriangleDupilumab (NCT06088771)
Dupilumab trial for Non-Small Cell Lung Cancer (NCT06088771). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for early stage non small cell lung cancer that can be removed by surgery, in adults.
The idea: give immunotherapy before surgery. On day 1, patients receive dupilumab, which targets IL 4 receptor alpha, by two injections under the skin, and cemiplimab, an anti PD 1 antibody, by vein. Standard surgery is scheduled around day 15. Patients are then followed for side effects.
This phase 1 and 2 trial plans 21 patients. At the Icahn School of Medicine at Mount Sinai in New York, Thomas Marron leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.